Clinical Trial Update: Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19 [Phase 2]

View source ↗

Summary

A randomized Phase IIA trial evaluated ivermectin for achieving negative PCR results in early-phase COVID-19 patients; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection
• Sars-cov Infection

Drugs mentioned

• IVERMECTIN (Ivermectin)

Snippet

Sponsor: Universidad Peruana Cayetano Heredia | Conditions: Covid19, Coronavirus Infection | Phase 2 | Status: COMPLETED